Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Brain tissue and pathology

Topic: Brain proteins, microglia and lab models

Plain-language summary

Alzheimer's disease is characterized by β-amyloid plaques and tau tangles. Plasma levels of phospho-tau217 (P-tau217) accurately differentiate Alzheimer's disease dementia from other dementias, but it is unclear to what degree this reflects β-amyloid plaque accumulation, tau tangle accumulation, or both. In a cohort with post-mortem neuropathological data (N = 88), both plaque and tangle density contributed independently to higher P-tau217, but P-tau217 was not elevated in patients with non-Alzheimer's disease tauopathies (N = 9).

What this study adds

Evidence grade: Moderate

The record lists 88 participants. In 88 people whose brains were examined after death, both amyloid plaques and tau tangles were independently linked to higher blood P-tau217, while levels were not raised in 9 people with other (non-Alzheimer's) tau diseases. In 426 living people scanned with PET (BioFINDER-2), P-tau217 tracked amyloid in early disease and both amyloid and, more strongly, tau in later disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mattsson-Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., et al. (2021). Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO molecular medicine. https://doi.org/10.15252/emmm.202114022

Vancouver

Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO molecular medicine. 2021. doi:10.15252/emmm.202114022. PMID: 33949133.

BibTeX

@article{mattssoncarlgren2021-33949133,
  author  = {Mattsson-Carlgren, N. and Janelidze, S. and Bateman, R. J. and Smith, R. and Stomrud, E. and Serrano, G. E. and Reiman, E. M. and Palmqvist, S. and others},
  title   = {{Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau}},
  journal = {EMBO molecular medicine},
  year    = {2021},
  doi     = {10.15252/emmm.202114022},
  pmid    = {33949133},
  url     = {https://doi.org/10.15252/emmm.202114022}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 88 people whose brains were examined after death, both amyloid plaques and tau tangles were independently linked to higher blood P-tau217, while levels were not raised in 9 people with other (non-Alzheimer's) tau diseases. In 426 living people scanned with PET (BioFINDER-2), P-tau217 tracked amyloid in early disease and both amyloid and, more strongly, tau in later disease. This is an association study supporting P-tau217 as a blood marker of Alzheimer's brain changes; it tests no treatment, and the non-Alzheimer's comparison is small.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 61 of 100.61 of 100 points earned39 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (EMBO molecular medicine)
Journal's citation record 2 / 4 EMBO Molecular Medicine: journal h-index 186 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 1 / 4 88 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 256 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 36.6 citations a year over 7 year(s) since 2021
Impact for its field and year 4 / 6 Cited 17.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 52 other studies in this library
Still being cited 3 / 4 Cited 160 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 33949133)
Free to read 2 / 2 Free to read
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

52 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Brain tissue and pathology from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain tissue and pathology

See all studies in Brain tissue and pathology →